Genetics of Addiction: How Much Is Inherited?

The clearest finding in the genetics of addiction is also the most misunderstood. Twin and adoption studies, run across decades and across substance classes, consistently estimate that 40 to 60 percent of the risk for any substance use disorder is inherited [1][2]. That number is large enough to take seriously as a clinical risk factor and small enough to leave the outcome unfixed. The remainder of the risk is environment, trauma, age of first use, and access, all of which can be modified. This article walks through the heritability estimate, the biological systems involved, how genes and environment interact, what family history changes in treatment, and what genetic testing for addiction can and cannot do.

The basic heritability estimate

Twin and adoption studies are the standard method for separating genetic from environmental contributions to a complex trait. By comparing identical twins, who share 100 percent of their DNA, with fraternal twins, who share roughly 50 percent, researchers can estimate what fraction of variation in a condition is attributable to genes [3].

For substance use disorders, the consistent estimate is that 40 to 60 percent of the risk is genetic [1][2]. The number varies modestly by substance. Alcohol use disorder lands near the middle of that range at roughly 50 percent heritability [3]. Cannabis and nicotine fall in a similar band. Cocaine and opioid use disorder cluster higher, with several reviews citing 60 to 70 percent [1][2].

What this means in plain language: with identical environments, the person whose biological parent had a substance use disorder would have roughly twice to four times the risk of developing one themselves [1]. A family history of addiction in alcohol use disorder or opioid use disorder is one of the strongest single risk factors in the clinical literature.

What genetic risk actually means

There is no single addiction gene, and there will not be one. What runs in families is the combined inheritance of dozens to hundreds of common gene variants, each contributing a small piece of risk [4]. The variants influence several different biological systems, and the inherited vulnerability shows up in the way these systems behave under exposure to a substance.

Four systems carry most of the clinical weight. Each has measurable variation in the general population, and each shifts in known directions in people at elevated risk for substance use disorder.

• Metabolism. Genes that control how the body breaks down alcohol, opioids, nicotine, and other substances. The ADH1B and ALDH2 variants in alcohol metabolism are the textbook example: some variants produce faster metabolism, some produce slower, and the slower variants produce a flushing reaction that meaningfully lowers risk of heavy drinking [3][4].
• Reward sensitivity. Genes affecting dopamine receptors, transporters, and signaling pathways in the mesolimbic reward circuit. Variants that produce a blunted baseline reward signal can paradoxically increase substance use, as the person seeks larger inputs to reach a normal felt state [5]. See how addiction changes the brain's reward system for the underlying circuitry.
• Stress response. Genes affecting the HPA axis and stress regulation. Variants that produce a more reactive stress response increase the pull toward substances as self-medication, particularly under chronic adversity [4].
• Impulse control. Genes affecting prefrontal cortex function and executive control. Variants associated with less effective impulse regulation raise risk of early use and faster escalation to a disorder once use begins [4].

How genes and environment combine

Genetic risk does not produce addiction on its own. It produces vulnerability that may or may not be expressed, depending on what happens in the environment. The most useful single statistic for this point is the identical-twin concordance rate. Identical twins share 100 percent of their DNA, and they are concordant for substance use disorder only about 50 to 60 percent of the time [3]. The twin who develops a disorder and the twin who does not share a genome, and they lived different lives.

Two interaction patterns matter most clinically, because each is modifiable.

Early exposure amplifies genetic risk. A person with high genetic vulnerability who first uses substances in early adolescence is at substantially higher risk of developing a disorder than the same person whose first use is in their late twenties [2]. The adolescent prefrontal cortex is still developing into the mid-twenties, and substance exposure during that window has outsized neurodevelopmental effects. Delaying first use, even by a few years, meaningfully reduces lifetime risk.

Trauma amplifies genetic risk. Adverse childhood experiences interact with genetic vulnerability such that a person with both high ACE exposure and high genetic loading has compound elevation of substance-use risk [6]. The CDC-Kaiser ACE study documented a dose-response curve linking childhood trauma to adult addiction risk, and the curve is steeper for people with strong family history. See trauma, ACEs, and addiction risk for the full picture.

What family history means for treatment

A family history of addiction is one of the most clinically informative facts a patient can bring to intake. It changes screening, it changes the treatment plan, it changes the family work, and it does not worsen the prognosis.

Earlier and more aggressive screening. Adolescents and young adults with a family history benefit from earlier conversations about substance use, well before any use begins. Pediatric visits, school-based screening, and family conversations are all reasonable places to start.

Treatment-plan tailoring. Knowing that a patient comes from a family with addiction history sharpens the clinical picture. The substance of choice may be familiar in the family, co-occurring mental health patterns often repeat across generations, and certain interventions, including medication-assisted treatment, may have an even stronger evidence base for a patient whose disorder is heavily genetic [7]. At The Archangel Centers, the MAT formulary includes Suboxone, Vivitrol, and Sublocade.

Family-system work. A multi-generation addiction pattern means the family system has been organized around the disease for a long time. Roles, communication, and expectations all need direct attention. Family programming addresses these patterns alongside the individual treatment plan.

Prognosis is not worsened by genetic loading. Patients with strong family histories respond to evidence-based treatment as well as patients without genetic loading, and in many clinical pictures the engagement is faster because the diagnosis is more obvious to the patient and the family [4]. Genetic risk is a clinical fact that sharpens the plan, not a verdict that limits it.

What genetic testing for addiction does and does not do

Direct-to-consumer genetic tests for addiction risk are commercially available, but they have limited utility for an individual treatment decision [8]. Polygenic risk scores predict population-level differences in risk, but they are not precise enough at the individual level to change clinical decisions. A score tells you whether your risk is somewhat above or below average. It does not tell you whether you will develop a substance use disorder.

Pharmacogenomic testing is a different category. These panels examine variants that affect how the body metabolizes specific medications, and the results can sometimes inform medication choice in psychiatry and addiction care [8]. Your clinical team will recommend it if it is indicated for your case. It is not a routine part of intake.

The honest framing: a test result, on its own, will not change the treatment plan. The family history conversation almost always does. Walk into intake with the family history. The test panel can come later if a specific medication question makes it useful.

What this means for treatment at The Archangel Centers

The founder-led work at The Archangel Centers, anchored in co-founder Mike Sorrentino's long-term sobriety, treats family history as one of the most useful pieces of clinical information a patient brings to intake. The outpatient continuum runs from Partial Care (called Day Treatment in New Jersey) through Intensive Outpatient, Outpatient, and Virtual Treatment. New Jersey Partial Care programming runs 9:00 AM to 3:15 PM Monday through Friday, with Saturday programming from 9:00 AM to 12:30 PM. Within that structure, family history shapes the assessment, the medication conversation, the trauma work, and the family-system pieces of the plan.

If the pattern in your family is starting to repeat, the most important point from the genetics literature is that the outcome is still open. Inherited risk is not a sentence. Treatment works, and it works as well for people with strong family history as for anyone else.